Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 15, Issue 3, 2014, Pages 228-235

  Raz Pasteur, Ayelet ^a   Gamliel Lazarovich, Aviva ^a   Gantman, Anna ^a   Coleman, Raymond ^b   Keidar, Shlomo ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Aldosterone; atherosclerosis; eplerenone; inflammation; low salt diet; macrophages; mineralocorticoid receptor

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; APOLIPOPROTEIN E; CHOLESTEROL; EPLERENONE; MINERALOCORTICOID RECEPTOR; BIOLOGICAL MARKER; MINERALOCORTICOID ANTAGONIST; RENIN; SPIRONOLACTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA ATHEROSCLEROSIS; ARTICLE; CONTROLLED STUDY; LIPID PEROXIDATION; MACROPHAGE; MOUSE; NONHUMAN; OXIDATION; PERITONEUM MACROPHAGE; PLASMA RENIN ACTIVITY; PROTEIN DEFICIENCY; SODIUM RESTRICTION; ANALOGS AND DERIVATIVES; ANIMAL; AORTA; ATHEROSCLEROSIS; BLOOD; DEFICIENCY; DRUG EFFECTS; HUMAN; INFLAMMATION; METABOLISM; PATHOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ALDOSTERONE; ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; DIET, SODIUM-RESTRICTED; HUMANS; INFLAMMATION; MACROPHAGES, PERITONEAL; MICE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, MINERALOCORTICOID; RENIN; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE;

EID: 84909944582     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320312467558     Document Type: Article

References (30)

1. Schneider EG, Taylor RE, Radke KJ, Davis PG. Effect of sodium concentration on aldosterone secretion by isolated perfused canine adrenal glands. Endocrinology. 1984 ; 115: 2195-2204
2. Meneton P, Jeunemaitre X, de Wardener HE, MacGregor GA. Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiol Rev. 2005 ; 85: 679-715
3. Graudal NA, Galløe AM, Garred P. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: A meta-analysis. JAMA. 1998 ; 279: 1383-1391
4. Ivanovski O, Szumilak D, Nguyen-Khoa T, et al. Dietary salt restriction accelerates atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 2005 ; 180: 271-276
5. Gamliel-Lazarovich A, Gantman A, Coleman R, Jeng AY, Kaplan M, Keidar S. FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice. J Hypertens. 2010 ; 28: 1900-1907
6. Lu H, Wu C, Howatt DA, Balakrishnan A, Charnigo RJ, Cassis LA, Daugherty A. Differential effects of dietary sodium intake on blood pressure and atherosclerosis in hypercholesterolemic mice. J Nutr Biochem.:
7. Tikellis C, Pickering RJ, Tsorotes D, et al. Activation of the renin-angiotensin system mediates the effects of dietary salt intake on atherogenesis in the apolipoprotein e knockout mouse. Hypertension. 2012 ; 60: 98-105
8. Funder JW. Aldosterone and mineralocorticoid receptors in the cardiovascular system. Prog Cardiovasc Dis. 2010 ; 52 (5). 393-400
9. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005 ; 45 (8). 1243-1248
10. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 ; 341: 709-717
11. Pitt B, Remme W, Zannad F. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 ; 348: 1309-1321
12. Keidar S, Hayek T, Kaplan M, et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2003 ; 41: 955-963
13. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation. 2002 ; 105: 2212-2216
14. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 2004 ; 109: 2213-2220
15. Aviram M, Vaya J. Markers for low-density lipoprotein oxidation. Methods Enzymol. 2001 ; 335: 244-256
16. Aviram M. Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients. Biochem Med. 1993 ; 30: 111-118
17. Smythe CD, Skinner VO, Bruckdorfer KR, Haskard DO, Landis RC. The state of macrophage differentiation determines the TNF alpha response to nitrated lipoprotein uptake. Atherosclerosis. 2003 ; 170: 213-221
18. Rita OD, Hackam DG, Spence JD. Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. Can J Cardiol.:
19. Takai S, Jin D, Muramatsu M, Kirimura K, Sakonjo H, Miyazaki M. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension. 2005 ; 46: 1135-1139
20. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells. Circ Res. 2005 ; 96: 643-650
21. Luther JM, Luo P, Wang Z, Cohen SE, Kim HS, Fogo AB, Brown NJ. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury. Kidney Int.:
22. Chai W, Danser AH. Why are mineralocorticoid receptor antagonists cardioprotective?. Naunyn Schmiedebergs Arch Pharmacol. 2006 ; 374: 153-162
23. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002 ; 283: H1802-1810
24. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology. 2002 ; 143: 4828-4836
25. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension. 2009 ; 54: 537-543
26. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schütz G, Lumeng CN, Mortensen RM. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest. 2010 ; 120: 3350-3364
27. Hansen PR, Rieneck K, Bendtzen K. Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. Immunol Lett. 2004 ; 91: 87-91
28. Mikkelsen M, Sønder SU, Nersting J, Bendtzen K. Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression. Apoptosis. 2006 ; 11: 573-579
29. Catanozi S, Rocha JC, Passarelli M, et al. Dietary sodium chloride restriction enhances aortic wall lipid storage and raises plasma lipid concentration in LDL receptor knockout mice. J Lipid Res. 2003 ; 44: 727-732
30. Soran H, Hama S, Yadav R, Durrington PN. HDL functionality. Curr Opin Lipidol.: